Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 37, pages 553–557 (2006)Cite this article

A Corrigendum to this article was published on 16 August 2006

An Erratum to this article was published on 17 May 2006

Abstract

Whether the CD34+ and CD3+ cell doses in allogeneic HSCT should be estimated using actual (ABW) or ideal (IBW) body weight has never been definitively determined. We have shown that CD34+ cell doses based upon IBW are better predictive of engraftment after autologous and allogeneic HSCT. Sixty-three patients undergoing reduced-intensity HSCT after a uniform preparative regimen were evaluated to determine the effect of cell dose. ABW and IBW were 45–147 kg (median 79) and 52–85 kg (median 67) respectively. The ABW-IBW difference was −24% to +133% (median +16%); nine patients were >5% underweight and 41 were >5% overweight. The CD34+ cell dose (106/kg) was 1.4–11.8 (median 5) by IBW and 1.2–9.3 (median 4.5) by ABW. The CD3+ cell dose (108/kg) was 0.9–14.9 (median 3) by IBW and 0.7–19.7 (median 2.7) by ABW. While CD34+ and CD3+ cell doses based upon IBW were found to affect transplant-related mortality, and disease-free and overall survival significantly, those based on ABW were either not predictive of outcome or the differences were of borderline significance. We suggest using IBW rather than ABW to calculate cell doses for HSCT; for statistical analyses and for clinical practice if a specific cell dose is being targeted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506.

    CAS  PubMed  Google Scholar 

  2. Barrett AJ, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323–3327.

    CAS  PubMed  Google Scholar 

  3. Paulin T . Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant 1992; 6: 48–54.

    CAS  PubMed  Google Scholar 

  4. Ringden O, Nilsson B . Death by graft-versus-host disease associated with HLA-mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44.

    Article  CAS  PubMed  Google Scholar 

  5. Bacigalupo A, Piaggio G, Podesta M, Figari O, Benvenuto F, Sogno G et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 221–226.

    CAS  PubMed  Google Scholar 

  6. Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996; 18: 741–746.

    CAS  PubMed  Google Scholar 

  7. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.

    CAS  PubMed  Google Scholar 

  8. Hjiyannakis P, Mehta J, Milan S, Powles R, Hinson J, Tait D . Melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukaemia: review of transplant-related mortality. Leuk Lymphoma 1997; 25: 565–572.

    Article  Google Scholar 

  9. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226–4235.

    CAS  PubMed  Google Scholar 

  10. Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Singhal S . Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood 1997; 90: 3808–3810.

    CAS  PubMed  Google Scholar 

  11. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Millar B et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489–496.

    Article  CAS  PubMed  Google Scholar 

  12. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000; 96: 4096–4102.

    CAS  PubMed  Google Scholar 

  13. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577.

    Article  CAS  PubMed  Google Scholar 

  14. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells? Blood 2001; 98: 2352–2357.

    Article  CAS  PubMed  Google Scholar 

  15. Dominietto A, Lamparelli A, Raiola AM, Van Lint MT, Gualandi F, Berisso G et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930–3934.

    Article  CAS  PubMed  Google Scholar 

  16. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867–873.

    Article  CAS  PubMed  Google Scholar 

  17. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861–864.

    Article  CAS  PubMed  Google Scholar 

  18. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman MS et al. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161–164.

    Article  CAS  PubMed  Google Scholar 

  19. Devine DJ . Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–655.

    Article  Google Scholar 

  20. Mehta J, Powles R, Singhal S, Horton C, Middleton G, Eisen T et al. Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 1997; 19: 349–355.

    Article  CAS  PubMed  Google Scholar 

  21. Singhal S, Gordon L, Meagher R, Evens A, Tallman M, Williams S et al. The CD34+ cell dose, even in an ‘acceptable’ range, affects outcome of allogeneic blood stem cell transplantation. Blood 2004; 104 (ASH Annual Meeting Abstracts) 1153.

    Google Scholar 

  22. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470.

    CAS  PubMed  Google Scholar 

  23. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    Article  CAS  PubMed  Google Scholar 

  24. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    S Singhal, L I Gordon, M S Tallman, J N Winter, A O Evens, O Frankfurt, S F Williams, D Grinblatt, L Kaminer, R Meagher & J Mehta

Authors
  1. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L I Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M S Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J N Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A O Evens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Frankfurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S F Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Grinblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Kaminer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Meagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Singhal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singhal, S., Gordon, L., Tallman, M. et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37, 553–557 (2006). https://doi.org/10.1038/sj.bmt.1705282

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705282

Keywords

This article is cited by

Search

Advanced search

Quick links